The Mifepristone Litigation: Untangling the Implications of the Fifth Circuit's Decision for Abortion Access and the US Food and Drug Administration

Editorial Material Medicine, General & Internal

Science v. Ideology in Court: Mifepristone and the US Food and Drug Administration

Wendy K. Mariner

ANNALS OF INTERNAL MEDICINE (2023)

Add to Collection

Editorial Material Medicine, General & Internal

The Mifepristone Case and the Legitimacy of the FDA

Abbe R. Gluck

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Editorial Material Medicine, General & Internal

Alliance for Hippocratic Medicine v. FDA - Dobbs's Collateral Consequences for Pharmaceutical Regulation

Patricia J. Zettler et al.

Summary: The Alliance for Hippocratic Medicine challenges the FDA's approval of mifepristone, raising concerns about potential restrictions on medication abortion access and the possibility of removing the drug from the U.S. market.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Editorial Material Multidisciplinary Sciences

Judicial interference with mifepristone

Margaret Hamburg et al.

SCIENCE (2023)

Add to Collection

Editorial Material Medicine, General & Internal

The New Threat to Abortion Access in the United States-The Comstock Act

I. Glenn Cohen et al.

Summary: This Viewpoint provides an explanation of the Comstock Act's history, how it has been utilized by those who seek to restrict abortion, and the potential impact it has on abortion access in the US.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Review Obstetrics & Gynecology

The next two decades of mifepristone at FDA: History as destiny

Eli Y. Adashi et al.

Summary: Congressional and presidential records indicate a consistent pattern of political interference with the FDA's regulatory authority over mifepristone. This article examines the ongoing legislative and legal disputes surrounding mifepristone, which comes just after its 20th anniversary of FDA approval for medical termination of intrauterine pregnancy.

CONTRACEPTION (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Pushing Back with Pills - Enhancing Access to Reproductive Health Drugs after Dobbs

Lewis A. Grossman

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Ethics

Mifepristone, preemption, and public health federalism

Patricia J. Zettler et al.

Summary: On June 24, 2022, the Supreme Court overturned Roe v Wade, prompting scholars and advocates to consider legal strategies to mitigate the anticipated harmful consequences. This article explores one such strategy involving preemption challenges to state restrictions on FDA-approved pregnancy termination drugs. The article argues that many state restrictions should be deemed preempted, and also examines the implications of preemption challenges in the abortion context for other areas of state drug regulation, asserting that public health federalism can still be upheld.

JOURNAL OF LAW AND THE BIOSCIENCES (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Ensuring Safe Access to Mifepristone During the Pandemic and Beyond

Beatrice L. Brown et al.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

The Mifepristone Litigation: Untangling the Implications of the Fifth Circuit's Decision for Abortion Access and the US Food and Drug Administration

Related references

Export Citation

Share Paper